Chapter 5 Polyglutamine Ataxias: In Vitro and In Vivo Models

Blue Books of Neurology

Volumn 31, Issue C, 2007, Pages 145-169

  Paulson, Henry L ^a   Pulst, Stefan M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957122567     PISSN: 1877184X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1877-184X(09)70079-6     Document Type: Article

References (98)

1. Taroni F., and DiDonato S. Pathways to motor incoordination: the inherited ataxias. Nat Rev Neurosci 5 (2004) 641-655
2. Schols L., et al. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 3 (2004) 291-304
3. Gu X., et al. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46 (2005) 433-444
4. Gatchel J.R., and Zoghbi H.Y. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 6 (2005) 743-755
5. Smith R., Brundin P., and Li J.Y. Synaptic dysfunction in Huntington's disease: a new perspective. Cell Mol Life Sci 62 (2005) 1901-1912
6. Muchowski P.J., and Wacker J.L. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6 (2005) 11-22
7. Ross C.A., and Poirier M.A. Protein aggregation and neurodegenerative disease. Nat Med 10 Suppl (2004) S10-S17
8. Lipinski M.M., and Yuan J. Mechanisms of cell death in polyglutamine expansion diseases. Curr Opin Pharmacol 4 (2004) 85-90
9. La Spada A.R., and Taylor J.P. Polyglutamines placed into context. Neuron 38 (2003) 681-684
10. Ross C.A. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?. Neuron 19 (1997) 1147-1150
11. Masino S.A., and Dulla C.G. Adenosine, glutamate and pH: interactions and implications. Neurol Res 27 (2005) 149-152
12. Yang W., et al. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 11 (2002) 2905-2917
13. Arrasate M., et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431 (2004) 805-810
14. Yoo S.Y., et al. SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron 37 (2003) 383-401
15. Orr H.T., and Zoghbi H.Y. SCA1 molecular genetics: a history of a 13 year collaboration against glutamines. Hum Mol Genet 10 (2001) 2307-2311
16. Bowman A.B., et al. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Human Mol Genet 14 (2005) 679-691
17. Berke S.J., and Paulson H.L. Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. Curr Opin Genet Dev 13 (2003) 253-261
18. Warrick J.M., et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 23 (1999) 425-428
19. Fernandez-Funez P., et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408 (2000) 101-106
20. Kazemi-Esfarjani P., and Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 287 (2000) 1837-1840
21. Warrick J.M., et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 93 (1998) 939-949
22. Nollen E.A., et al. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc Natl Acad Sci USA 101 (2004) 6403-6408
23. Chan H.Y., et al. Mechanisms of chaperone suppression of polyglutamine disease: selectivity synergy and modulation of protein solubility in Drosophila. Hum Mol Genet 9 (2000) 2811-2820
24. Miller V.M., et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 100 (2003) 7195-7200
25. Cummings C.J., et al. Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet 10 (2001) 1511-1518
26. Helmlinger D., et al. Hsp70 and Hsp40 chaperones do not modulate retinal phenotype in SCA7 mice. J Biol Chem 279 (2004) 55969-55977
27. Holmberg C.I., et al. Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J 23 (2004) 4307-4318
28. Venkatraman P., et al. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 14 (2004) 95-104
29. Bence N.F., Sampat R.M., and Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292 (2001) 1552-1555
30. Chai Y., et al. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet 8 (1999) 673-682
31. Schaffar G., et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell 15 (2004) 95-105
32. McMahon S.J., et al. Polyglutamine-expanded spinocerebellar ataxia-7 protein disrupts normal SAGA and SLIK histone acetyltransferase activity. Proc Natl Acad Sci USA 102 (2005) 8478-8482
33. Palhan V.B., et al. Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc Natl Acad Sci USA 102 (2005) 8472-8477
34. Helmlinger D., et al. Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum Mol Genet 13 (2004) 1257-1265
35. Tsuda H., et al. The AXH domain of ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins. Cell 122 (2005) 633-644
36. McCampbell A., et al. CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 9 (2000) 2197-2202
37. Restituito S., et al. The polyglutamine expansion in spinocerebellar ataxia type 6 causes a beta subunit-specific enhanced activation of P/Q-type calcium channels in Xenopus oocytes. J Neurosci 20 (2000) 6394-6403
38. Fletcher C.F., et al. Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 87 (1996) 607-617
39. Hirakura Y., et al. Polyglutamine-induced ion channels: a possible mechanism for the neurotoxicity of Huntington and other CAG repeat diseases. J Neurosci Res 60 (2000) 490-494
40. Monoi H., et al. Poly-L-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. Biophys J 78 (2000) 2892-2899
41. Gunawardena S., and Goldstein L.S. Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch Neurol 62 (2005) 46-51
42. Yang Q., et al. Morphological Purkinje cell changes in spinocerebellar ataxia type 6. Acta Neuropathol (Berl) 100 (2000) 371-376
43. Burnett B.G., and Pittman R.N. The polyglutamine neurodegenerative protein ataxin 3 regulates aggre-some formation. Proc Natl Acad Sci USA 102 (2005) 4330-4335
44. Gunawardena S., et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40 (2003) 25-40
45. Cemal C.K., et al. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet 11 (2002) 1075-1094
46. Klement I.A., et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95 (1998) 41-53
47. Irwin S., et al. RNA association and nucleocytoplasmic shuttling by ataxin-1. J Cell Sci 118 (2005) 233-242
48. Chai Y., et al. Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci USA 99 (2002) 9310-9315
49. Kim S., et al. Polyglutamine protein aggregates are dynamic. Nat Cell Biol 4 (2002) 826-831
50. Stenoien D.L., Mielke M., and Mancini M.A. Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components. Nat Cell Biol 4 (2002) 806-810
51. Emamian E.S., et al. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38 (2003) 375-387
52. Chen H.K., et al. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113 (2003) 457-468
53. Kaytor M.D., et al. A cell-based screen for modulators of ataxin-1 phosphorylation. Hum Mol Genet 14 (2005) 1095-1105
54. Huynh D.P., et al. Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. Hum Mol Genet 12 (2003) 1485-1496
55. Shibata H., Huynh D.P., and Pulst S.M. A novel protein with RNA-binding motifs interacts with ataxin-2. Hum Mol Genet 9 (2000) 1303-1313
56. Ralser M., et al. Ataxin-2 and huntingtin interact with endophilin-A complexes to function in plastin-associated pathways. Hum Mol Genet 14 (2005) 2893-2909
57. Ralser M., et al. An integrative approach to gain insights into the cellular function of human ataxin-2. J Mol Biol 346 (2005) 203-214
58. Hofmann K., and Falquet L. A ubiquitin-interacting motif conserved in components of the protea-somal and lysosomal protein degradation systems. Trends Biochem Sci 26 (2001) 347-350
59. Scheel H., Tomiuk S., and Hofmann K. Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics. Hum Mol Genet 12 (2003) 2845-2852
60. Burnett B., Li F., and Pittman R.N. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum Mol Genet 12 (2003) 3195-3205
61. Doss-Pepe E.W., et al. Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. Mol Cell Biol 23 (2003) 6469-6483
62. Donaldson K.M., et al. Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. Proc Natl Acad Sci USA 100 (2003) 8892-8897
63. Chai Y., et al. Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J Biol Chem 279 (2004) 3605-3611
64. Berke S.J., et al. Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3. J Biol Chem 280 (2005) 32026-32034
65. Warrick J.M., et al. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell 18 (2005) 37-48
66. Riley B.E., Zoghbi H.Y., and Orr H.T. SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal. J Biol Chem 280 (2005) 21942-21948
67. Berke S.J., et al. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J Neurochem 89 (2004) 908-918
68. Goti D., et al. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci 24 (2004) 10266-10279
69. Hu Q., et al. The carboxy-terminal tail region of human Cav2.1 (P/Q-type) channel is not an essential determinant for its subcellular localization in cultured neurones. Genes Cells 10 (2005) 87-96
70. Kubodera T., et al. Proteolytic cleavage and cellular toxicity of the human alpha1A calcium channel in spinocerebellar ataxia type 6. Neurosci Lett 341 (2003) 74-78
71. 2+ channel currents arising from expanded trinucleotide repeats in spinocerebellar ataxia type 6. J Neurosci 21 (2001) 9185-9193
72. Chen S., et al. Interference of Crx-dependent transcription by ataxin-7 involves interaction between the glutamine regions and requires the ataxin-7 carboxy-terminal region for nuclear localization. Hum Mol Genet 13 (2004) 53-67
73. Burright E.N., et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82 (1995) 937-948
74. La Spada A.R., et al. Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron 31 (2001) 913-927
75. Lorenzetti D., et al. Repeat instability and motor incoordination in mice with a targeted expanded CAG repeat in the Sca1 locus. Hum Mol Genet 9 (2000) 779-785
76. Matilla A., et al. Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation. J Neurosci 18 (1998) 5508-5516
77. Grewal R.P., et al. Clinical features and ATTCT repeat expansion in spinocerebellar ataxia type 10. Arch Neurol 59 (2002) 1285-1290
78. Yvert G., et al. Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Hum Mol Genet 9 (2000) 2491-2506
79. Clark H.B., et al. Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations. J Neurosci 17 (1997) 7385-7395
80. Skinner P.J., et al. Altered trafficking of membrane proteins in Purkinje cells of SCA1 transgenic mice. Am J Pathol 159 (2001) 905-913
81. Cummings C.J., et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24 (1999) 879-892
82. Chen Y.W. Local protein unfolding and pathogenesis of polyglutamine-expansion diseases. Proteins 51 (2003) 68-73
83. Watase K., et al. Regional differences of somatic CAG repeat instability do not account for selective neuronal vulnerability in a knock-in mouse model of SCA1. Hum Mol Genet 12 (2003) 2789-2795
84. Ranum L.P., et al. Molecular and clinical correlations in spinocerebellar ataxia type I: evidence for familial effects on the age at onset. Am J Hum Genet 55 (1994) 244-252
85. Pulst S.M., et al. Spinocerebellar ataxia type 2: polyQ repeat variation in the CACNA1A calcium channel modifies age of onset. Brain 128 (2005) 2297-2303
86. Zu I., et al. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J Neurosci 24 (2004) 8853-8861
87. Pulst S.M., et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 14 (1996) 269-276
88. Imbert G., et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 14 (1996) 285-291
89. Pulst S. Neurogenetics. 1st ed. (2003), Academic Press, San Diego 45-56
90. Huynh D.P., et al. Nucleas localization or inclusion body formation are not necessary for SCA2 pathogenesis in mouse or human. Nature Genet 26 (2000) 44-50
91. Kiehl T.R., et al. Generation and characterization of Sca2 (ataxin-2) knockout mice. Biochem Biophys Res Commun 339 (2006) 17-24
92. Ikeda H., et al. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet 13 (1996) 196-202
93. Yvert G., et al. SCA7 mouse models show selective stabilization of mutant ataxin-7 and similar cellular responses in different neuronal cell types. Hum Mol Genet 10 (2001) 1679-1692
94. Garden G.A., et al. Polyglutamate-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. J Neurosci 22 (2002) 4897-4905
95. Libby R.T., et al. Genomic context drives SCA7 CAG repeat instability while expressed SCA7 cDNAs are intergenerationally and somatically stable in transgenic mice. Hum Mol Genet 12 (2003) 41-50
96. Xia H., et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10 (2004) 816-820
97. Xia H., et al. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 20 (2002) 1006-1010
98. Miller V.M., et al. CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J Neurosci 25 (2005) 9152-9161